diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-6231diaendo-6231Research ArticleСтатьиArticlesТерапия глибенкламидом: за или против?Glibenclamide therapy: pros and consВикуловаОльга КонстантиновнаVikulovaOlga Konstantinovnaolga-vikulova-1973@yandex.ruШестаковаМарина ВладимировнаShestakovaMarina Vladimirovna-ФГУ Эндокринологический научный центр, МоскваEndocrinology Research Centre, Moscow201115092011143№3 (2011)9296Copyright © Викулова О.К., Шестакова М.В., 20112011Викулова О.К., Шестакова М.В.Vikulova O.K., Shestakova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/6231

Безопасность сахароснижающей терапии у пациентов c сахарным диабетом 2 типа (СД2) является одной из наиболее широко обсуж-даемых проблем в последние годы. И хотя однозначного мнения по данной проблеме нет, по данным ряда исследований терапия глибен-кламидом ассоциируется с повышением риска сердечно-сосудистой патологии, в частности инфаркта миокарда, и риска смертностипо сравнению с другими препаратами СМ (гликлазидом и глимепиридом).

The safety of antidiabetic medications has received much attention in the resent past. Although concerns on the safety of glibenclamide therapy iscontroversial, some studies showed an increased risk of cardiovascular morbidity (f.e. myocardial infarction) and risk of mortality in subjects usingglibenclamide, but not other SU (gliclazide or glimepiride)

сахарный диабет 2 типаглибенкламидгипогликемиясмертностьdiabetes mellitus type 2glibenclamidehypoglysemiamortalityReferencesSulsburg D.S. The UGDP study // JAMA. - 1971. - № 218. - Р. 1704-1705.Sulsburg D.S. The UGDP study // JAMA. - 1971. - № 218. - Р. 1704-1705.UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compered with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - № 352. - Р. 837-853.UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compered with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - № 352. - Р. 837-853.Kahn S.E., Haffner S.M., Heise M.A., et al. for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy // N. Engl. J. Med. - 2006. - № 355. - Р. 2427-2443.Kahn S.E., Haffner S.M., Heise M.A., et al. for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy // N. Engl. J. Med. - 2006. - № 355. - Р. 2427-2443.Cleveland Jr. J.C., Meldrum D.R., Cain B.S., Banerjee A., Harken A.H. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited // Circulation. - 1997. - № 96. - Р. 29-32.Cleveland Jr. J.C., Meldrum D.R., Cain B.S., Banerjee A., Harken A.H. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited // Circulation. - 1997. - № 96. - Р. 29-32.Klepzig H., Kober G., Matter C. et al. Sulfonylureas and ischemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide // Eur Heart J. - 1999. - № 20. - Р. 439-446.Klepzig H., Kober G., Matter C. et al. Sulfonylureas and ischemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide // Eur Heart J. - 1999. - № 20. - Р. 439-446.Maddock H.L., Siedlecka S.M., Yellon D.M. Myocardial protection from either ischemic preconditioning or nicorandil is not blocked by gliclazide // Cardiovasc Drugs Ther. - 2004. - № 18. - Р. 113-119.Maddock H.L., Siedlecka S.M., Yellon D.M. Myocardial protection from either ischemic preconditioning or nicorandil is not blocked by gliclazide // Cardiovasc Drugs Ther. - 2004. - № 18. - Р. 113-119.Mocanu M.M., Maddock H.L., Baxter G.F. et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide // Circulation. - 2001. - № 103. - Р. 3111-3116.Mocanu M.M., Maddock H.L., Baxter G.F. et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide // Circulation. - 2001. - № 103. - Р. 3111-3116.Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N. et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study //European Heart Journal. - 2011; doi:10.1093/eurheartj/ehr077.Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N. et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study //European Heart Journal. - 2011; doi:10.1093/eurheartj/ehr077.UK Prospective Diabetes Study (UKPDS) GrouP. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - № 352. - Р. 854-865.UK Prospective Diabetes Study (UKPDS) GrouP. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - № 352. - Р. 854-865.Khalangot M., Tronko M., Kravchenko V., Kovtun V. Glibenclamiderelated excess in total and ardiovascular mortality risks: data from large Ukrainian observational cohort study // Diabetes Res Clin Pract. - 2009. - № 86. - Р. 247-253.Khalangot M., Tronko M., Kravchenko V., Kovtun V. Glibenclamiderelated excess in total and ardiovascular mortality risks: data from large Ukrainian observational cohort study // Diabetes Res Clin Pract. - 2009. - № 86. - Р. 247-253.Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., Novials A., Rottiers R., Rutten G.E.H.M., Shaw K.M. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients // European Journal of Clinical Investigation. - 2004. - № 34. - Р. 535-542.Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., Novials A., Rottiers R., Rutten G.E.H.M., Shaw K.M. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients // European Journal of Clinical Investigation. - 2004. - № 34. - Р. 535-542.Patel A., MacMahon S., Chalmers J., Neal B. et al. The ADVANCE Collaborative GrouP. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. - 2008. - № 358. - Р. 2560-2572.Patel A., MacMahon S., Chalmers J., Neal B. et al. The ADVANCE Collaborative GrouP. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. - 2008. - № 358. - Р. 2560-2572.Thisted H., Johnsen S.P., Rungby J. Sulphonylureas and the risk of myocardial infarction // Metabolism. - 2006. - № 55. - S16-S19.Thisted H., Johnsen S.P., Rungby J. Sulphonylureas and the risk of myocardial infarction // Metabolism. - 2006. - № 55. - S16-S19.Johnsen S.P., Monster T.B., Olsen M.L. et al. Risk and short-term prognosis of myocardial infarction among users of antidibetic drugs // Am J Ther. - 2006. - № 13. - Р. 134-140.Johnsen S.P., Monster T.B., Olsen M.L. et al. Risk and short-term prognosis of myocardial infarction among users of antidibetic drugs // Am J Ther. - 2006. - № 13. - Р. 134-140.Zeller M., Danchin N., Simon D. et al. Impact f type preadmission sulphonylureas on mortality and cardiovascular outcmes in diabetic patients with acute myocardial infarction // J. Clin. Endocrin. Metab. - 2010. - doi: 10.1210/jc.2010-0449.Zeller M., Danchin N., Simon D. et al. Impact f type preadmission sulphonylureas on mortality and cardiovascular outcmes in diabetic patients with acute myocardial infarction // J. Clin. Endocrin. Metab. - 2010. - doi: 10.1210/jc.2010-0449.Monami M., Balzi D., Lamanna C., Barchielli et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer related mortality // Diabetes Metab Res Rev. - 2007. - № 23. - Р. 479-484.Monami M., Balzi D., Lamanna C., Barchielli et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer related mortality // Diabetes Metab Res Rev. - 2007. - № 23. - Р. 479-484.Cacciapuoti F., Spiezia R., Bianchi U. et al. Effectiveness of glibenclamide on myocarial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus // Am. J. Cardiol. - 1991. - № 67. - Р. 843-847.Cacciapuoti F., Spiezia R., Bianchi U. et al. Effectiveness of glibenclamide on myocarial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus // Am. J. Cardiol. - 1991. - № 67. - Р. 843-847.Lomuscio A., Vergani D., Marano L., Castagnone M., Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction // Coron. Artery. Dis. - 1994. - № 5(9). - Р. 767-771.Lomuscio A., Vergani D., Marano L., Castagnone M., Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction // Coron. Artery. Dis. - 1994. - № 5(9). - Р. 767-771.del Valle H.F., Lascano E.C., Negroni J.A., Crottogini A.J. Glibenclamide effects on reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep // Cardiovascular Research. - 2001. - № 50. - Р. 474-485.del Valle H.F., Lascano E.C., Negroni J.A., Crottogini A.J. Glibenclamide effects on reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep // Cardiovascular Research. - 2001. - № 50. - Р. 474-485.Xianghua F., Weili W., Yangmei Y., Xuechao W. et al. Adverse effects of glibenclamide on myocardia perfusion in patients with acute myocardial infarction and type 2 diabetes mellitus. GWICC Abstracts 2010 // Heart. - 2010. - № 96: A126-A127Xianghua F., Weili W., Yangmei Y., Xuechao W. et al. Adverse effects of glibenclamide on myocardia perfusion in patients with acute myocardial infarction and type 2 diabetes mellitus. GWICC Abstracts 2010 // Heart. - 2010. - № 96: A126-A127Salas M., Caro J.J. Are hypoglycemia and other adverse effects similar among sulphonylureas // Advers Drug react Toxicol Rev. - 2002. - № 21. - Р. 205-217.Salas M., Caro J.J. Are hypoglycemia and other adverse effects similar among sulphonylureas // Advers Drug react Toxicol Rev. - 2002. - № 21. - Р. 205-217.Gangji A.S., Cukierman T., Gerstein H.C. et al. A systematic review and meta-analysis f hypoglycemia and cardiovascular events. A comparison of glyburide with other secretagogues and insulin // Diabetes care. - 2007. - № 30(2). - Р. 389-394.Gangji A.S., Cukierman T., Gerstein H.C. et al. A systematic review and meta-analysis f hypoglycemia and cardiovascular events. A comparison of glyburide with other secretagogues and insulin // Diabetes care. - 2007. - № 30(2). - Р. 389-394.Wei M., Gibbons L.W., Mitchell T.L. et al. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality // Circulation. - 2000. - № 101(17). - Р. 2047-2052.Wei M., Gibbons L.W., Mitchell T.L. et al. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality // Circulation. - 2000. - № 101(17). - Р. 2047-2052.Draeger K.E., Wernicke-Panten K., Lomp H.J. et al. Long-term treatment of type two diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide // Horm. Metab. Res. - 1996. - № 28. - Р. 419-425.Draeger K.E., Wernicke-Panten K., Lomp H.J. et al. Long-term treatment of type two diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide // Horm. Metab. Res. - 1996. - № 28. - Р. 419-425.Marbury T., Huang W.C., Strange P., Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial // Diabetes Res. Clin. Pract. - 1999. - № 43. - Р. 155-166.Marbury T., Huang W.C., Strange P., Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial // Diabetes Res. Clin. Pract. - 1999. - № 43. - Р. 155-166.Gerstein H.C., Miller M.E., Byington R.P., Goff D.C. et al. The Action to Control Cardiovascular Risk in Diabetes Study Group: effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. - 2008. - № 358. - Р. 2545-2559.Gerstein H.C., Miller M.E., Byington R.P., Goff D.C. et al. The Action to Control Cardiovascular Risk in Diabetes Study Group: effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. - 2008. - № 358. - Р. 2545-2559.Nathan D.M., Buse J.B., Davidson M.B. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association of the study of diabetes // Diabetes care. - 2008. - № 31. - Р. 1-11.Nathan D.M., Buse J.B., Davidson M.B. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association of the study of diabetes // Diabetes care. - 2008. - № 31. - Р. 1-11.Дедов И.И., Шестакова М.В., Аметов А.С., Анциферов М.Б., Галстян г.Р., Майоров А.Ю., Мкртумян А.М, Петунина Н.А., Сухарева О.Ю. Проект «Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа» // Сахарный диабет. - 2011. - № 1(50). - С. 95-105.Дедов И.И., Шестакова М.В., Аметов А.С., Анциферов М.Б., Галстян г.Р., Майоров А.Ю., Мкртумян А.М, Петунина Н.А., Сухарева О.Ю. Проект «Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа» // Сахарный диабет. - 2011. - № 1(50). - С. 95-105.

The authors declare that there are no conflicts of interest present.